Pharmacogenomics. Knowledge. Implementation.

Gene:
ABCG2
ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group)

Clinical PGx
PGx Research
Overview
Pathways
Is Related To
Publications
LinkOuts

Prescribing Info (1) Drug Labels (0) Clinical Annotations (31)

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Clinical Annotation for rs2231142 (ABCG2), allopurinol and Gout (level 2B Efficacy)

Level of Evidence: Level 2B
Type: Efficacy
Variant: rs2231142
Genes: ABCG2
Phenotypes: Gout
OMB Race: Mixed Population

To see the rest of this clinical annotation please register or sign in.

Clinical Annotation for rs2231142 (ABCG2), rosuvastatin, Hypercholesterolemia and Myocardial Infarction (level 2B Efficacy)

Level of Evidence: Level 2B
Type: Efficacy
Variant: rs2231142
Genes: ABCG2
Phenotypes: Hypercholesterolemia, Myocardial Infarction
OMB Race: Mixed Population
Race Notes: White, Asian, or unknown.

To see the rest of this clinical annotation please register or sign in.

Clinical Annotation for rs4148157 (ABCG2), topotecan and Brain Neoplasms (level 3 Metabolism/PK)

Level of Evidence: Level 3
Type: Metabolism/PK
Variant: rs4148157
Genes: ABCG2
Phenotypes: Brain Neoplasms
OMB Race: Unknown

To see the rest of this clinical annotation please register or sign in.

Clinical Annotation for rs12505410 (ABCG2), imatinib and Leukemia, Myelogenous, Chronic, BCR-ABL Positive (level 3 Efficacy)

Level of Evidence: Level 3
Type: Efficacy
Variant: rs12505410
Genes: ABCG2
Phenotypes: Leukemia, Myelogenous, Chronic, BCR-ABL Positive
OMB Race: Unknown

To see the rest of this clinical annotation please register or sign in.

Clinical Annotation for rs13120400 (ABCG2), methotrexate and Psoriasis (level 3 Efficacy)

Level of Evidence: Level 3
Type: Efficacy
Variant: rs13120400
Genes: ABCG2
Phenotypes: Psoriasis
OMB Race: Unknown

To see the rest of this clinical annotation please register or sign in.

Clinical Annotation for rs13120400 (ABCG2), imatinib and Leukemia, Myelogenous, Chronic, BCR-ABL Positive (level 3 Efficacy)

Level of Evidence: Level 3
Type: Efficacy
Variant: rs13120400
Genes: ABCG2
Phenotypes: Leukemia, Myelogenous, Chronic, BCR-ABL Positive
OMB Race: Unknown

To see the rest of this clinical annotation please register or sign in.

Clinical Annotation for rs13120400 (ABCG2), deferasirox and beta-Thalassemia (level 3 Efficacy, Metabolism/PK)

Level of Evidence: Level 3
Type: Efficacy, Metabolism/PK
Variant: rs13120400
Genes: ABCG2
Phenotypes: beta-Thalassemia
OMB Race: Unknown

To see the rest of this clinical annotation please register or sign in.

Clinical Annotation for rs2231142 (ABCG2), atorvastatin (level 3)

Level of Evidence: Level 3
Type: Other
Variant: rs2231142
Genes: ABCG2
OMB Race: White

To see the rest of this clinical annotation please register or sign in.

Clinical Annotation for rs2231142 (ABCG2), fluvastatin (level 3)

Level of Evidence: Level 3
Type: Other
Variant: rs2231142
Genes: ABCG2
OMB Race: White

To see the rest of this clinical annotation please register or sign in.

Clinical Annotation for rs2231142 (ABCG2), simvastatin (level 3)

Level of Evidence: Level 3
Variant: rs2231142
Genes: ABCG2
OMB Race: White

To see the rest of this clinical annotation please register or sign in.

Clinical Annotation for rs2231142 (ABCG2), sulfasalazine and Arthritis, Rheumatoid (level 3 Efficacy)

Level of Evidence: Level 3
Type: Efficacy
Variant: rs2231142
Genes: ABCG2
Phenotypes: Arthritis, Rheumatoid
OMB Race: Mixed Population

To see the rest of this clinical annotation please register or sign in.

Clinical Annotation for rs2231142 (ABCG2), sunitinib and Neoplasms (level 3 Toxicity/ADR)

Level of Evidence: Level 3
Type: Toxicity/ADR
Variant: rs2231142
Genes: ABCG2
Phenotypes: Neoplasms
OMB Race: Mixed Population

To see the rest of this clinical annotation please register or sign in.

Clinical Annotation for rs2231142 (ABCG2), gefitinib and Lung Neoplasms (level 3 Toxicity/ADR)

Level of Evidence: Level 3
Type: Toxicity/ADR
Variant: rs2231142
Genes: ABCG2
Phenotypes: Lung Neoplasms
OMB Race: Mixed Population

To see the rest of this clinical annotation please register or sign in.

Clinical Annotation for rs2231142 (ABCG2), lamotrigine and Epilepsy (level 3 Efficacy, Metabolism/PK)

Level of Evidence: Level 3
Type: Efficacy, Metabolism/PK
Variant: rs2231142
Genes: ABCG2
Phenotypes: Epilepsy
OMB Race: Asian
Race Notes: Han Chinese

To see the rest of this clinical annotation please register or sign in.

Clinical Annotation for rs2231142 (ABCG2), capecitabine, fluorouracil, leucovorin, oxaliplatin and Colorectal Neoplasms (level 3 Efficacy)

Level of Evidence: Level 3
Type: Efficacy
Variant: rs2231142
Genes: ABCG2
Phenotypes: Colorectal Neoplasms
OMB Race: Unknown

To see the rest of this clinical annotation please register or sign in.

Clinical Annotation for rs2231142 (ABCG2), sulfasalazine (level 3 Metabolism/PK)

Level of Evidence: Level 3
Type: Metabolism/PK
Variant: rs2231142
Genes: ABCG2
OMB Race: Asian

To see the rest of this clinical annotation please register or sign in.

Clinical Annotation for rs17731538 (ABCG2), methotrexate and Psoriasis (level 3 Efficacy)

Level of Evidence: Level 3
Type: Efficacy
Variant: rs17731538
Genes: ABCG2
Phenotypes: Psoriasis
OMB Race: Unknown

To see the rest of this clinical annotation please register or sign in.

Clinical Annotation for rs2231137 (ABCG2), irinotecan and Carcinoma, Non-Small-Cell Lung (level 3 Toxicity/ADR)

Level of Evidence: Level 3
Type: Toxicity/ADR
Variant: rs2231137
Genes: ABCG2
Phenotypes: Carcinoma, Non-Small-Cell Lung
OMB Race: Asian
Race Notes: Korean

To see the rest of this clinical annotation please register or sign in.

Clinical Annotation for rs2725252 (ABCG2), imatinib and Leukemia, Myelogenous, Chronic, BCR-ABL Positive (level 3 Efficacy)

Level of Evidence: Level 3
Type: Efficacy
Variant: rs2725252
Genes: ABCG2
Phenotypes: Leukemia, Myelogenous, Chronic, BCR-ABL Positive
OMB Race: Unknown

To see the rest of this clinical annotation please register or sign in.

Clinical Annotation for rs2231135 (ABCG2), methotrexate and Osteosarcoma (level 3 Toxicity/ADR)

Level of Evidence: Level 3
Type: Toxicity/ADR
Variant: rs2231135
Genes: ABCG2
Phenotypes: Osteosarcoma
OMB Race: Unknown

To see the rest of this clinical annotation please register or sign in.

Clinical Annotation for rs3114020 (ABCG2), lamotrigine and Epilepsy (level 3 Metabolism/PK)

Level of Evidence: Level 3
Type: Metabolism/PK
Variant: rs3114020
Genes: ABCG2
Phenotypes: Epilepsy
OMB Race: Asian

To see the rest of this clinical annotation please register or sign in.

Clinical Annotation for rs7699188 (ABCG2), fluorouracil, irinotecan, leucovorin and Colorectal Neoplasms (level 3 Efficacy, Toxicity/ADR)

Level of Evidence: Level 3
Type: Efficacy, Toxicity/ADR
Variant: rs7699188
Genes: ABCG2
Phenotypes: Colorectal Neoplasms
OMB Race: White

To see the rest of this clinical annotation please register or sign in.

Clinical Annotation for rs2199939 (ABCG2), rosuvastatin (level 3 Efficacy)

Level of Evidence: Level 3
Type: Efficacy
Variant: rs2199939
Genes: ABCG2
OMB Race: White

To see the rest of this clinical annotation please register or sign in.

Clinical Annotation for rs45605536 (ABCG2), dasatinib and imatinib (level 4)

Level of Evidence: Level 4
Type: Other
Variant: rs45605536
Genes: ABCG2
OMB Race: Unknown
Race Notes: in-vitro

To see the rest of this clinical annotation please register or sign in.

Clinical Annotation for rs58818712 (ABCG2), dasatinib and imatinib (level 4)

Level of Evidence: Level 4
Type: Other
Variant: rs58818712
Genes: ABCG2
OMB Race: Unknown
Race Notes: in-vitro

To see the rest of this clinical annotation please register or sign in.

Clinical Annotation for rs41282401 (ABCG2), dasatinib, imatinib and nilotinib (level 4)

Level of Evidence: Level 4
Type: Other
Variant: rs41282401
Genes: ABCG2
OMB Race: Unknown
Race Notes: in-vitro

To see the rest of this clinical annotation please register or sign in.

Clinical Annotation for rs1061018 (ABCG2), dasatinib, imatinib and nilotinib (level 4)

Level of Evidence: Level 4
Type: Other
Variant: rs1061018
Genes: ABCG2
OMB Race: Unknown
Race Notes: in-vitro

To see the rest of this clinical annotation please register or sign in.

Clinical Annotation for rs2231142 (ABCG2), efavirenz, HIV and HIV Infections (level 4 Toxicity/ADR)

Level of Evidence: Level 4
Type: Toxicity/ADR
Variant: rs2231142
Genes: ABCG2
Phenotypes: HIV, HIV Infections
OMB Race: White
Race Notes: Caucasian.

To see the rest of this clinical annotation please register or sign in.

Clinical Annotation for rs2231142 (ABCG2), imatinib (level 4 Metabolism/PK)

Level of Evidence: Level 4
Type: Metabolism/PK
Variant: rs2231142
Genes: ABCG2
OMB Race: Unknown

To see the rest of this clinical annotation please register or sign in.

Clinical Annotation for rs72552713 (ABCG2), sulfasalazine (level 4 Metabolism/PK)

Level of Evidence: Level 4
Type: Metabolism/PK
Variant: rs72552713
Genes: ABCG2
OMB Race: Asian

To see the rest of this clinical annotation please register or sign in.

Clinical Annotation for rs2231137 (ABCG2), dasatinib, imatinib and nilotinib (level 4)

Level of Evidence: Level 4
Type: Other
Variant: rs2231137
Genes: ABCG2
OMB Race: Unknown
Race Notes: in-vitro

To see the rest of this clinical annotation please register or sign in.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

List of all variant annotations for ABCG2

	Variant? (147)	Alternate Names ?	Chemicals ?	Alleles ? (+ chr strand)	Function ?	Amino Acid? Translation
VA	rs10011796	NC_000004.11:g.89090877T>C, NC_000004.12:g.88169725T>C, NG_032067.2:g.66598A>G, NM_001257386.1:c.-19-29711A>G, XM_005263355.1:c.-19-29711A>G, XM_005263355.2:c.-19-29711A>G, XM_011532420.1:c.-19-29711A>G, rs61380906	allopurinol	T > C	SNP
CA VA	rs1061018	NC_000004.11:g.89042853A>G, NC_000004.12:g.88121701A>G, NG_032067.2:g.114622T>C, NM_001257386.1:c.623T>C, NM_004827.2:c.623T>C, NP_001244315.1:p.Phe208Ser, NP_004818.2:p.Phe208Ser, XM_005263354.1:c.623T>C, XM_005263354.2:c.623T>C, XM_005263355.1:c.623T>C, XM_005263355.2:c.623T>C, XM_005263356.1:c.623T>C, XM_005263356.2:c.623T>C, XM_011532420.1:c.623T>C, XP_005263411.1:p.Phe208Ser, XP_005263412.1:p.Phe208Ser, XP_005263413.1:p.Phe208Ser, XP_011530722.1:p.Phe208Ser, rs386514545	nilotinib dasatinib imatinib	A > G	SNP	F208S
CA VA	rs12505410	NC_000004.11:g.89030841T>G, NC_000004.12:g.88109689T>G, NG_032067.2:g.126634A>C, NM_001257386.1:c.1195-2423A>C, NM_004827.2:c.1195-2423A>C, XM_005263354.1:c.1195-2423A>C, XM_005263354.2:c.1195-2423A>C, XM_005263355.1:c.1195-2423A>C, XM_005263355.2:c.1195-2423A>C, XM_005263356.1:c.1189-2423A>C, XM_005263356.2:c.1189-2423A>C, XM_011532420.1:c.1195-2423A>C	imatinib	T > G	SNP
CA VA	rs13120400	NC_000004.11:g.89033527T>C, NC_000004.12:g.88112375T>C, NG_032067.2:g.123948A>G, NM_001257386.1:c.1194+928A>G, NM_004827.2:c.1194+928A>G, XM_005263354.1:c.1194+928A>G, XM_005263354.2:c.1194+928A>G, XM_005263355.1:c.1194+928A>G, XM_005263355.2:c.1194+928A>G, XM_005263356.1:c.1188+928A>G, XM_005263356.2:c.1188+928A>G, XM_011532420.1:c.1194+928A>G	methotrexate deferasirox imatinib	T > C	SNP
VA	rs1481012	NC_000004.11:g.89039082A>G, NC_000004.12:g.88117930A>G, NG_032067.2:g.118393T>C, NM_001257386.1:c.841+179T>C, NM_004827.2:c.841+179T>C, XM_005263354.1:c.841+179T>C, XM_005263354.2:c.841+179T>C, XM_005263355.1:c.841+179T>C, XM_005263355.2:c.841+179T>C, XM_005263356.1:c.841+179T>C, XM_005263356.2:c.841+179T>C, XM_011532420.1:c.841+179T>C, rs56635010, rs60335926	rosuvastatin	A > G	SNP
CA VA	rs17731538	NC_000004.11:g.89055379G>A, NC_000004.12:g.88134227G>A, NG_032067.2:g.102096C>T, NM_001257386.1:c.204-1592C>T, NM_004827.2:c.204-1592C>T, XM_005263354.1:c.204-1592C>T, XM_005263354.2:c.204-1592C>T, XM_005263355.1:c.204-1592C>T, XM_005263355.2:c.204-1592C>T, XM_005263356.1:c.204-1592C>T, XM_005263356.2:c.204-1592C>T, XM_011532420.1:c.204-1592C>T, rs57419238	methotrexate antiepileptics	G > A	SNP
VA	rs17731799	NC_000004.11:g.89068455G>T, NC_000004.12:g.88147303G>T, NG_032067.2:g.89020C>A, NM_001257386.1:c.-19-7289C>A, NM_004827.2:c.-19-7289C>A, XM_005263354.1:c.-19-7289C>A, XM_005263354.2:c.-19-7289C>A, XM_005263355.1:c.-19-7289C>A, XM_005263355.2:c.-19-7289C>A, XM_005263356.1:c.-19-7289C>A, XM_005263356.2:c.-19-7289C>A, XM_011532420.1:c.-19-7289C>A, rs74288523	antiepileptics	G > T	SNP
CA VA	rs2199939	NC_000008.10:g.39911494C>T, NC_000008.11:g.40053975C>T	rosuvastatin	C > T	SNP
CA VA	rs2231135	NC_000004.11:g.89079994A>G, NC_000004.12:g.88158842A>G, NG_032067.2:g.77481T>C, NM_001257386.1:c.-19-18828T>C, NM_004827.2:c.-476T>C, XM_005263354.1:c.-285T>C, XM_005263354.2:c.-285T>C, XM_005263355.1:c.-19-18828T>C, XM_005263355.2:c.-19-18828T>C, XM_005263356.1:c.-476T>C, XM_005263356.2:c.-476T>C, XM_011532420.1:c.-19-18828T>C, rs57106183	methotrexate	A > G	SNP
CA VA	rs2231137	NC_000004.11:g.89061114C>T, NC_000004.12:g.88139962C>T, NG_032067.2:g.96361G>A, NM_001257386.1:c.34G>A, NM_004827.2:c.34G>A, NP_001244315.1:p.Val12Met, NP_004818.2:p.Val12Met, XM_005263354.1:c.34G>A, XM_005263354.2:c.34G>A, XM_005263355.1:c.34G>A, XM_005263355.2:c.34G>A, XM_005263356.1:c.34G>A, XM_005263356.2:c.34G>A, XM_011532420.1:c.34G>A, XP_005263411.1:p.Val12Met, XP_005263412.1:p.Val12Met, XP_005263413.1:p.Val12Met, XP_011530722.1:p.Val12Met	sorafenib lamotrigine nilotinib methotrexate irinotecan valganciclovir talinolol antiepileptics sunitinib pravastatin dasatinib imatinib	C > T	SNP	V12M
CA VA	rs2231142	NC_000004.11:g.89052323G>T, NC_000004.12:g.88131171G>T, NG_032067.2:g.105152C>A, NM_001257386.1:c.421C>A, NM_004827.2:c.421C>A, NP_001244315.1:p.Gln141Lys, NP_004818.2:p.Gln141Lys, XM_005263354.1:c.421C>A, XM_005263354.2:c.421C>A, XM_005263355.1:c.421C>A, XM_005263355.2:c.421C>A, XM_005263356.1:c.421C>A, XM_005263356.2:c.421C>A, XM_011532420.1:c.421C>A, XP_005263411.1:p.Gln141Lys, XP_005263412.1:p.Gln141Lys, XP_005263413.1:p.Gln141Lys, XP_011530722.1:p.Gln141Lys, rs12721641, rs28365035, rs3736117, rs52809243, rs58973676	palonosetron leucovorin dasatinib sorafenib levofloxacin pazopanib fluorouracil hmg coa reductase inhibitors irinotecan acetaminophen deferasirox efavirenz granisetron pravastatin felodipine imatinib antineoplastic agents n-desethyl sunitinib capecitabine selumetinib tacrolimus sulfasalazine atorvastatin talinolol rosuvastatin diflomotecan simvastatin fluvastatin lamotrigine nilotinib oxaliplatin methotrexate gefitinib antiepileptics sunitinib allopurinol	G > T	SNP	Q141K
VA	rs2231148	NC_000004.11:g.89028478T>A, NC_000004.12:g.88107326T>A, NG_032067.2:g.128997A>T, NM_001257386.1:c.1195-60A>T, NM_004827.2:c.1195-60A>T, XM_005263354.1:c.1195-60A>T, XM_005263354.2:c.1195-60A>T, XM_005263355.1:c.1195-60A>T, XM_005263355.2:c.1195-60A>T, XM_005263356.1:c.1189-60A>T, XM_005263356.2:c.1189-60A>T, XM_011532420.1:c.1195-60A>T	antiepileptics	T > A	SNP
VA	rs2231164	NC_000004.11:g.89015857C>T, NC_000004.12:g.88094705C>T, NG_032067.2:g.141618G>A, NM_001257386.1:c.1728-46G>A, NM_004827.2:c.1738-46G>A, XM_005263354.1:c.1738-46G>A, XM_005263354.2:c.1738-46G>A, XM_005263355.1:c.1738-46G>A, XM_005263355.2:c.1738-46G>A, XM_005263356.1:c.1732-46G>A, XM_005263356.2:c.1732-46G>A, XM_011532420.1:c.1738-46G>A, rs3816742, rs386561805, rs59707155	antineoplastic agents	C > A C > T	SNP
VA	rs2622604	NC_000004.11:g.89078924T>C, NC_000004.12:g.88157772T>C, NG_032067.2:g.78551A>G, NM_001257386.1:c.-19-17758A>G, NM_004827.2:c.-20+614A>G, XM_005263354.1:c.-20+805A>G, XM_005263354.2:c.-20+805A>G, XM_005263355.1:c.-19-17758A>G, XM_005263355.2:c.-19-17758A>G, XM_005263356.1:c.-20+614A>G, XM_005263356.2:c.-20+614A>G, XM_011532420.1:c.-19-17758A>G, rs61481684	irinotecan sunitinib gefitinib erlotinib	T > A T > C	SNP
VA	rs2622628	NC_000004.11:g.89029252A>C, NC_000004.12:g.88108100A>C, NG_032067.2:g.128223T>G, NM_001257386.1:c.1195-834T>G, NM_004827.2:c.1195-834T>G, XM_005263354.1:c.1195-834T>G, XM_005263354.2:c.1195-834T>G, XM_005263355.1:c.1195-834T>G, XM_005263355.2:c.1195-834T>G, XM_005263356.1:c.1189-834T>G, XM_005263356.2:c.1189-834T>G, XM_011532420.1:c.1195-834T>G, rs386570725, rs59698865, rs61074534	lamotrigine antiepileptics	A > C	SNP
CA VA	rs2725252	NC_000004.11:g.89061910C>A, NC_000004.12:g.88140758C>A, NG_032067.2:g.95565G>T, NM_001257386.1:c.-19-744G>T, NM_004827.2:c.-19-744G>T, XM_005263354.1:c.-19-744G>T, XM_005263354.2:c.-19-744G>T, XM_005263355.1:c.-19-744G>T, XM_005263355.2:c.-19-744G>T, XM_005263356.1:c.-19-744G>T, XM_005263356.2:c.-19-744G>T, XM_011532420.1:c.-19-744G>T, rs386572685	imatinib	C > A	SNP
VA	rs2725256	NC_000004.11:g.89050998A>G, NC_000004.12:g.88129846A>G, NG_032067.2:g.106477T>C, NM_001257386.1:c.531+1215T>C, NM_004827.2:c.531+1215T>C, XM_005263354.1:c.531+1215T>C, XM_005263354.2:c.531+1215T>C, XM_005263355.1:c.531+1215T>C, XM_005263355.2:c.531+1215T>C, XM_005263356.1:c.531+1215T>C, XM_005263356.2:c.531+1215T>C, XM_011532420.1:c.531+1215T>C, rs386572687, rs56882964	antiepileptics	A > G	SNP
VA	rs2725264		irinotecan	C > T	SNP
VA	rs3109823	NC_000004.11:g.89064602C>T, NC_000004.12:g.88143450C>T, NG_032067.2:g.92873G>A, NM_001257386.1:c.-19-3436G>A, NM_004827.2:c.-19-3436G>A, XM_005263354.1:c.-19-3436G>A, XM_005263354.2:c.-19-3436G>A, XM_005263355.1:c.-19-3436G>A, XM_005263355.2:c.-19-3436G>A, XM_005263356.1:c.-19-3436G>A, XM_005263356.2:c.-19-3436G>A, XM_011532420.1:c.-19-3436G>A, rs56631287, rs59663973	antiepileptics	C > T	SNP
VA	rs3114018	NC_000004.11:g.89064581A>C, NC_000004.12:g.88143429A>C, NG_032067.2:g.92894T>G, NM_001257386.1:c.-19-3415T>G, NM_004827.2:c.-19-3415T>G, XM_005263354.1:c.-19-3415T>G, XM_005263354.2:c.-19-3415T>G, XM_005263355.1:c.-19-3415T>G, XM_005263355.2:c.-19-3415T>G, XM_005263356.1:c.-19-3415T>G, XM_005263356.2:c.-19-3415T>G, XM_011532420.1:c.-19-3415T>G, rs17731703, rs60824629	oxaliplatin	A > C	SNP
CA VA	rs3114020	NC_000004.11:g.89083666T>C, NC_000004.12:g.88162514T>C, NG_032067.2:g.73809A>G, NM_001257386.1:c.-19-22500A>G, XM_005263355.1:c.-19-22500A>G, XM_005263355.2:c.-19-22500A>G, XM_011532420.1:c.-19-22500A>G, rs13137608	lamotrigine antiepileptics	T > C	SNP
VA	rs3219191	NC_000004.11:g.89080717_89080718insTGAG, NC_000004.12:g.88159565_88159566insTGAG, NG_032067.2:g.76757_76758insCTCA, NM_001257386.1:c.-19-19552_-19-19551insCTCA, NM_004827.2:c.-1200_-1199insCTCA, XM_005263354.1:c.-1009_-1008insCTCA, XM_005263354.2:c.-1009_-1008insCTCA, XM_005263355.1:c.-19-19552_-19-19551insCTCA, XM_005263355.2:c.-19-19552_-19-19551insCTCA, XM_005263356.1:c.-1200_-1199insCTCA, XM_005263356.2:c.-1200_-1199insCTCA, XM_011532420.1:c.-19-19552_-19-19551insCTCA	antiepileptics	- > TGAG	indel
CA VA	rs41282401	NC_000004.11:g.89036166C>G, NC_000004.12:g.88115014C>G, NG_032067.2:g.121309G>C, NM_001257386.1:c.886G>C, NM_004827.2:c.886G>C, NP_001244315.1:p.Asp296His, NP_004818.2:p.Asp296His, XM_005263354.1:c.886G>C, XM_005263354.2:c.886G>C, XM_005263355.1:c.886G>C, XM_005263355.2:c.886G>C, XM_005263356.1:c.886G>C, XM_005263356.2:c.886G>C, XM_011532420.1:c.886G>C, XP_005263411.1:p.Asp296His, XP_005263412.1:p.Asp296His, XP_005263413.1:p.Asp296His, XP_011530722.1:p.Asp296His	nilotinib dasatinib imatinib	C > G	SNP	D296H
CA VA	rs4148157	NC_000004.11:g.89020934G>A, NC_000004.12:g.88099782G>A, NG_032067.2:g.136541C>T, NM_001257386.1:c.1368-334C>T, NM_004827.2:c.1368-334C>T, XM_005263354.1:c.1368-334C>T, XM_005263354.2:c.1368-334C>T, XM_005263355.1:c.1368-334C>T, XM_005263355.2:c.1368-334C>T, XM_005263356.1:c.1362-334C>T, XM_005263356.2:c.1362-334C>T, XM_011532420.1:c.1368-334C>T, rs56715039	topotecan antiepileptics	G > A	SNP
CA VA	rs45605536	NC_000004.11:g.89018670C>T, NC_000004.12:g.88097518C>T, NG_032067.2:g.138805G>A, NM_001257386.1:c.1582G>A, NM_004827.2:c.1582G>A, NP_001244315.1:p.Ala528Thr, NP_004818.2:p.Ala528Thr, XM_005263354.1:c.1582G>A, XM_005263354.2:c.1582G>A, XM_005263355.1:c.1582G>A, XM_005263355.2:c.1582G>A, XM_005263356.1:c.1576G>A, XM_005263356.2:c.1576G>A, XM_011532420.1:c.1582G>A, XP_005263411.1:p.Ala528Thr, XP_005263412.1:p.Ala528Thr, XP_005263413.1:p.Ala526Thr, XP_011530722.1:p.Ala528Thr	dasatinib imatinib	C > T	SNP	A528T
CA VA	rs58818712	NC_000004.11:g.89018678A>C, NC_000004.12:g.88097526A>C, NG_032067.2:g.138797T>G, NM_001257386.1:c.1574T>G, NM_004827.2:c.1574T>G, NP_001244315.1:p.Leu525Arg, NP_004818.2:p.Leu525Arg, XM_005263354.1:c.1574T>G, XM_005263354.2:c.1574T>G, XM_005263355.1:c.1574T>G, XM_005263355.2:c.1574T>G, XM_005263356.1:c.1568T>G, XM_005263356.2:c.1568T>G, XM_011532420.1:c.1574T>G, XP_005263411.1:p.Leu525Arg, XP_005263412.1:p.Leu525Arg, XP_005263413.1:p.Leu523Arg, XP_011530722.1:p.Leu525Arg, rs61735384	nilotinib dasatinib imatinib	A > C	SNP	L525R
CA VA	rs72552713	NC_000004.11:g.89052957G>A, NC_000004.12:g.88131805G>A, NG_032067.2:g.104518C>T, NM_001257386.1:c.376C>T, NM_004827.2:c.376C>T, NP_001244315.1:p.Gln126Ter, NP_004818.2:p.Gln126Ter, XM_005263354.1:c.376C>T, XM_005263354.2:c.376C>T, XM_005263355.1:c.376C>T, XM_005263355.2:c.376C>T, XM_005263356.1:c.376C>T, XM_005263356.2:c.376C>T, XM_011532420.1:c.376C>T, XP_005263411.1:p.Gln126Ter, XP_005263412.1:p.Gln126Ter, XP_005263413.1:p.Gln126Ter, XP_011530722.1:p.Gln126Ter	gefitinib pazopanib sulfasalazine	G > A	SNP	Q126*
CA VA	rs7699188	NC_000004.11:g.89096061G>A, NC_000004.12:g.88174909G>A, NG_032067.2:g.61414C>T, NM_001257386.1:c.-19-34895C>T, XM_005263355.1:c.-19-34895C>T, XM_005263355.2:c.-19-34895C>T, XM_011532420.1:c.-19-34895C>T, rs57955088	leucovorin irinotecan fluorouracil	G > A G > C	SNP

Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Alternate Names:	None
Alternate Symbols:	ABCP; BCRP; CD338; EST157481; MXR
PharmGKB Accession Id:	PA390

Details

Cytogenetic Location:	chr4 : q22.1 - q22.1
GP mRNA Boundary†:	chr4 : 89011416 - 89152569
GP Gene Boundary†:	chr4 : 89008416 - 89162569
Strand:	minus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser

† The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

Acetaminophen Pathway (therapeutic doses), Pharmacokinetics
Stylized diagram showing acetaminophen metabolism and transport in the liver.

Acetaminophen Pathway (toxic doses), Pharmacokinetics
Stylized diagram showing acetaminophen metabolism at higher acetaminophen doses (toxic doses) in the liver

Doxorubicin Pathway (Cancer Cell), Pharmacodynamics
Representation of the candidate genes involved in the action of doxorubicin in a stylized cancer cell.

Doxorubicin Pathway, Pharmacokinetics
Diagrammatic representation of the transport and metabolism of doxorubicin.

Erlotinib Pathway, Pharmacokinetics
Model human liver cell showing genes involved in the transportation and metabolism of Erlotinib.

Fluoropyrimidine Pathway, Pharmacokinetics
Representation of the metabolic pathways for fluoropyrimidines.

Gefitinib Pathway, Pharmacokinetics
Representation of the candidate genes involved in the transportation and metabolism of gefitinib.

Imatinib Pathway, Pharmacokinetics/Pharmacodynamics

Irinotecan Pathway, Pharmacodynamics
Model non-tissue specific cancer cell displaying genes which may be involved in the irinotecan pathway.

Irinotecan Pathway, Pharmacokinetics
Model human liver cell showing blood, bile and intestinal compartments, indicating tissue specific involvement of genes in the irinotecan pathway.

Lamivudine Pathway, Pharmacokinetics/Pharmacodynamics
Representation of candidate genes involved in the metabolism of lamivudine and its mechanism of antiviral action.

Methotrexate Pathway (Brain Cell), Pharmacokinetics
Representation of transport and exchange of methotrexate in the brain.

Methotrexate Pathway, Pharmacokinetics
Diagramatic representation of uptake, transport and elimination of methotrexate.

Pazopanib Pathway, Pharmacokinetics
Stylized representation of pazopanib transport and metabolism in the liver.

Platinum Pathway, Pharmacokinetics/Pharmacodynamics
Representation of the candidate genes involved in the metabolism of platinum containing drugs.

Pravastatin Pathway, Pharmacokinetics
Drug-specific representation of the candidate genes involved in transport, metabolism and clearance.

Statin Pathway - Generalized, Pharmacokinetics
Representation of the superset of all genes involved in the transport, metabolism and clearance of statin class drugs.

Taxane Pathway, Pharmacokinetics
Representation of the genes involved in the metabolism and transport of paclitaxel and docetaxel, and the downstream effects of the drugs.

Uricosurics Pathway, Pharmacodynamics
A stylized diagram of a renal proximal tubule cell to show the role of uricosuric drugs in preventing reabsorption of uric acid in human kidney.

Zidovudine Pathway, Pharmacokinetics/Pharmacodynamics
Representation of candidate genes involved in the metabolism of zidovudine and its mechanism of antiviral action.

Related Genes and Targets Related Drugs Related Diseases/Phenotypes

Curated Information ?

Evidence	Gene
PW	NR1I2
	SLCO1B1

Curated Information ?

Evidence	Drug
VA	acetaminophen
DL	afatinib
DL	alectinib
CA VA	allopurinol
CA VA	atorvastatin
CA	capecitabine
DL	dabrafenib
CA VA	dasatinib
CA VA	deferasirox
VA	diflomotecan
PW	docetaxel
DL	dolutegravir
PW	doxorubicin
CA VA	efavirenz
DL	eltrombopag
DL	Epclusa
VA PW	erlotinib
VA	felodipine
CA VA PW	fluorouracil
CA VA	fluvastatin
CA VA PW	gefitinib
VA	granisetron
CA VA PW	imatinib
CA VA	irinotecan
PW	lamivudine
CA VA	lamotrigine
CA VA	leucovorin
VA	levofloxacin
CA VA PW	methotrexate
VA	n-desethyl sunitinib
CA VA	nilotinib
CA VA	oxaliplatin
PW	paclitaxel
VA	palonosetron
DL VA	pazopanib
DL	ponatinib
VA PW	pravastatin
DL CA VA	rosuvastatin
DL	rucaparib
DL	ruxolitinib
VA	selumetinib
CA VA	simvastatin
PW	SN-38
DL	sofosbuvir
CA VA	sulfasalazine
CA VA	sunitinib
VA	tacrolimus
VA	talinolol
DL	technivie
CA VA	topotecan
VA	valganciclovir
DL	venetoclax
DL	Viekira Pak
PW	zidovudine

Evidence	Drug Class
VA	antiepileptics
VA	antineoplastic agents
VA PW	hmg coa reductase inhibitors
PW	Platinum compounds

Curated Information ?

Evidence	Disease
VA	Anemia
CA VA	Arthritis, Rheumatoid
CA VA	beta-Thalassemia
CA VA	Brain Neoplasms
VA	Burkitt Lymphoma
CA VA	Carcinoma, Non-Small-Cell Lung
VA	Carcinoma, Renal Cell
VA	Colonic Neoplasms
CA VA	Colorectal Neoplasms
VA	creatine kinase
VA	Diarrhea
VA	Drug Toxicity
CA VA	Epilepsy
VA	Gastrointestinal Stromal Tumors
CA VA	Gout
VA	hand-foot syndrome
CA	HIV
CA VA	HIV Infections
CA VA	Hypercholesterolemia
VA	Kidney Transplantation
VA	Leukemia
CA VA	Leukemia, Myelogenous, Chronic, BCR-ABL Positive
CA VA	Lung Neoplasms
VA	Lymphoma, T-Cell
VA	mucositis
VA	Muscular Diseases
CA VA	Myocardial Infarction
VA	Nausea
CA VA	Neoplasms
VA	nephrotoxicity
VA	Neutropenia
CA VA	Osteosarcoma
VA	overall survival
VA	Pancreatic Neoplasms
VA	Peripheral Nervous System Diseases
VA	Precursor Cell Lymphoblastic Leukemia-Lymphoma
VA	progression-free survival
CA VA	Psoriasis
VA	Rhabdomyolysis
VA	Thrombocytopenia
VA	Toxic liver disease
VA	Vomiting

Publications related to ABCG2: 172

VA	Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis. European journal of clinical pharmacology. 2017. Dymond Angela W, et al.
CA VA	Small-dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of Five Probes for OATP2B1 and BCRP. Journal of pharmaceutical sciences. 2017. Kashihara Yushi, et al.
VA	Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. Pharmacogenomics. 2017. Allegra Sarah, et al.
VA	The influence of CYP3A53 and BCRPC421A genetic polymorphisms on the pharmacokinetics of felodipine in healthy Chinese volunteers. Journal of clinical pharmacy and therapeutics.* 2017. Xiang Q, et al.
VA	Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis. Pharmacogenomics. 2017. Jiang Zhi-Ping, et al.
VA	Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters. Genome medicine. 2016. Matthaei Johannes, et al.
	Pharmacogenetics of drug transporters in modulating imatinib disposition and treatment outcomes in chronic myeloid leukemia & gastrointestinal stromal tumor patients. Pharmacogenomics. 2016. Chen Sylvia, et al.
VA	ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia. The pharmacogenomics journal. 2016. Li M, et al.
CA VA	Specific OCT1 and ABCG2 polymorphisms are associated with Lamotrigine concentrations in Chinese patients with epilepsy. Epilepsy research. 2016. Shen Chun-Hong, et al.
	Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity. Pharmacogenomics. 2016. Bins Sander, et al.
	Exploring Variation in Known Pharmacogenetic Variants and its Association with Drug Response in Different Mexican Populations. Pharmaceutical research. 2016. Gonzalez-Covarrubias Vanessa, et al.
	Pharmacogenomics and the treatment of acute myeloid leukemia. Pharmacogenomics. 2016. Megías-Vericat Juan Eduardo, et al.
VA	Multidrug Resistance-Associated Protein 4 (MRP4) controls ganciclovir intracellular accumulation and contributes to ganciclovir-induced neutropenia in renal transplant patients. Pharmacological research. 2016. Billat Pierre-André, et al.
	Evidence for extensive pleiotropy among pharmacogenes. Pharmacogenomics. 2016. Oetjens Matthew T, et al.
CA VA	Deferasirox AUC efficacy cutoff and role of pharmacogenetics. European journal of clinical pharmacology. 2016. Allegra S, et al.
VA	Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study. The pharmacogenomics journal. 2016. Tsuji D, et al.
CA VA	Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant. Drug metabolism and disposition: the biological fate of chemicals. 2016. Roberts Jessica K, et al.
VA	A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering. Pharmacogenomics. 2016. Leusink Maarten, et al.
CA VA	Role of pharmacogenetics on deferasirox AUC and efficacy. Pharmacogenomics. 2016. Cusato Jessica, et al.
VA	Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2016. Hirose Takashi, et al.
VA	Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2016. Kanai M, et al.
	Pharmacokinetics and Pharmacogenetics of Rosuvastatin in 30 healthy Zimbabwean individuals of African ancestry. British journal of clinical pharmacology. 2016. Soko Nyarai, et al.
	Genetic Variation among 82 Pharmacogenes: the PGRN-Seq data from the eMERGE Network. Clinical pharmacology and therapeutics. 2016. Bush William S, et al.
	Seventeen years of statin pharmacogenetics: a systematic review. Pharmacogenomics. 2016. Leusink Maarten, et al.
CA VA	ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout. The pharmacogenomics journal. 2016. Roberts R L, et al.
	Clinically relevant genetic variants of drug-metabolizing enzyme and transporter genes detected in Thai children and adolescents with autism spectrum disorder. Neuropsychiatric disease and treatment. 2016. Medhasi Sadeep, et al.
VA	Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug Reaction. PloS one. 2016. Low Siew-Kee, et al.
CA VA	Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate. The pharmacogenomics journal. 2015. Jabeen S, et al.
VA	Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma. Clinical genitourinary cancer. 2015. Noda Satoshi, et al.
CA VA	Polymorphisms of ABCG2, ABCB1 and HNF4alpha are associated with Lamotrigine trough concentrations in epilepsy patients. Drug metabolism and pharmacokinetics. 2015. Zhou Yafang, et al.
CA VA	Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer. Clinical lung cancer. 2015. Kobayashi Hiroyuki, et al.
VA	ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: a case-control study. Pharmacogenomics. 2015. Mirošević Skvrce Nikica, et al.
CA VA	Sulfasalazine disposition in a subject with 376C>T (nonsense mutation) and 421C>A variants in the ABCG2 gene. British journal of clinical pharmacology. 2015. Gotanda Keisuke, et al.
	Pharmacogenomic assessment of Mexican and Peruvian populations. Pharmacogenomics. 2015. Marsh Sharon, et al.
VA	IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma. British journal of cancer. 2015. Xu C-F, et al.
CA VA	Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response. Clinical pharmacology and therapeutics. 2015. Wen C C, et al.
CA VA	Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients. Investigational new drugs. 2015. Narjoz C, et al.
	A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors. Molecular cancer therapeutics. 2015. Kendra Kari L, et al.
VA	Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor. Cancer chemotherapy and pharmacology. 2015. Koo Dong-Hoe, et al.
CA VA	Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States. European journal of clinical pharmacology. 2015. Birmingham Bruce K, et al.
VA	Sunitinib-induced severe toxicities in a Japanese patient with the ABCG2 421 AA genotype. BMC cancer. 2014. Miura Yuji, et al.
	Pharmacogenetic considerations in the treatment of gout. Pharmacogenomics. 2015. Roberts Rebecca L, et al.
CA VA	Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma. PloS one. 2015. Chu Ying-Hsia, et al.
	Mechanisms and assessment of statin-related muscular adverse effects. British journal of clinical pharmacology. 2014. Moßhammer Dirk, et al.
VA	Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies. Pharmacogenomics. 2014. Suthandiram Sujatha, et al.
CA VA	Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis. The pharmacogenomics journal. 2014. Wiese M D, et al.
	Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach. Clinical pharmacology and therapeutics. 2014. Tsamandouras N, et al.
	Pharmacogenetics of childhood acute lymphoblastic leukemia. Pharmacogenomics. 2014. Lopez-Lopez Elixabet, et al.
	PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics. Pharmacogenetics and genomics. 2014. McDonagh Ellen M, et al.
	Development of a broad-based ADME panel for use in pharmacogenomic studies. Pharmacogenomics. 2014. Brown Andrew Mk, et al.
	Expression and activity of ABCG2, but not ABCB1 or OATP1B1, are associated with cholesterol levels: evidence from in vitro and in vivo experiments. Pharmacogenomics. 2014. To Kenneth Kw, et al.
	Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review. Genetics in medicine : official journal of the American College of Medical Genetics. 2014. Canestaro William J, et al.
	Pharmacogenetics of drug-induced birth defects: the role of polymorphisms of placental transporter proteins. Pharmacogenomics. 2014. Daud Aizati Na, et al.
	Interaction of the Efflux Transporters ABCB1 and ABCG2 With Imatinib, Nilotinib, and Dasatinib. Clinical pharmacology and therapeutics. 2014. Eadie L N, et al.
VA	Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2. European journal of clinical pharmacology. 2014. Ferrari Marco, et al.
CA VA	Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer. Medical oncology (Northwood, London, England). 2014. Zhao Jing, et al.
CA VA	Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line. Pharmacogenetics and genomics. 2014. Skoglund Karin, et al.
VA	Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy. International journal of hematology. 2013. Yanagimachi Masakatsu, et al.
VA	Association of ABCC2 -24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia. PloS one. 2014. Liu Yan, et al.
CA VA	Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients. Cancer chemotherapy and pharmacology. 2013. Kim Hye Ryun, et al.
CA VA	High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients. Oncotarget. 2013. Delord Marc, et al.
CA VA	Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment. Pharmacogenetics and genomics. 2013. De Mattia Elena, et al.
CA VA	Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circulation. Cardiovascular genetics. 2013. DeGorter Marianne K, et al.
VA	Levofloxacin-induced seizures in a patient without predisposing risk factors: the impact of pharmacogenetics. European journal of clinical pharmacology. 2013. Gervasoni Cristina, et al.
CA VA	Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. Pharmacogenomics. 2013. Lee Hon-Kit, et al.
	International transporter consortium commentary on clinically important transporter polymorphisms. Clinical pharmacology and therapeutics. 2013. Giacomini K M, et al.
	Transporters in drug development and clinical pharmacology. Clinical pharmacology and therapeutics. 2013. Giacomini K M, et al.
CA VA	Impact of pharmacogenetics on CNS side effects related to efavirenz. Pharmacogenomics. 2013. Sánchez Martín Almudena, et al.
	Emerging Transporters of Clinical Importance: An Update from the International Transporter Consortium. Clinical pharmacology and therapeutics. 2013. Hillgren Kathleen M, et al.
	Association of ATP-binding cassette transporter variants with the risk of Alzheimer's disease. Pharmacogenomics. 2013. Cascorbi Ingolf, et al.
	Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors. Pharmacogenomics. 2013. Spraggs Colin F, et al.
	The expression profile of ATP-binding cassette transporter genes in breast carcinoma. Pharmacogenomics. 2013. Hlaváč Viktor, et al.
	Gene Expression Profiling of Transporters in the Solute Carrier and ATP-Binding Cassette Superfamilies in Human Eye Substructures. Molecular pharmaceutics. 2012. Dahlin Amber, et al.
	ABCB1 variation and treatment response in AIDS patients: initial results of the Henan cohort. PloS one. 2013. Zhu Peng, et al.
	Pharmacogenomic update on multiple sclerosis: a focus on actual and new therapeutic strategies. The pharmacogenomics journal. 2012. Foti Cuzzola V, et al.
VA	Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2012. Xu C F, et al.
	The Novel BCR-ABL and FLT3 Inhibitor Ponatinib Is a Potent Inhibitor of the MDR-Associated ATP-Binding Cassette Transporter ABCG2. Molecular cancer therapeutics. 2012. Sen Rupashree, et al.
	The Dual Role of Pharmacogenetics in HIV Treatment: Mutations and Polymorphisms Regulating Antiretroviral Drug Resistance and Disposition. Pharmacological reviews. 2012. Michaud Veronique, et al.
CA VA	Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circulation. Cardiovascular genetics. 2012. Chasman Daniel I, et al.
VA	Genetic effects and modifiers of radiotherapy and chemotherapy on survival in pancreatic cancer. Pancreas. 2011. Zeng Hongmei, et al.
	Pharmacogenomics: the genetics of variable drug responses. Circulation. 2011. Roden Dan M, et al.
	Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs. 2011. Keisner Sidney V, et al.
VA	Gene-wide tagging study of the association between ABCC2, ABCC5 and ABCG2 genetic polymorphisms and multidrug resistance in epilepsy. Pharmacogenomics. 2011. Kwan Patrick, et al.
VA	Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011. van der Veldt Astrid A M, et al.
VA	Pharmacokinetics of intravenous paracetamol in elderly patients. Clinical pharmacokinetics. 2011. Liukas Antti, et al.
	Global patterns of genetic diversity and signals of natural selection for human ADME genes. Human molecular genetics. 2011. Li Jing, et al.
CA VA	Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. Pharmacogenomics. 2011. Lemos Clara, et al.
VA	Engraftment syndrome, but not acute GVHD, younger age, CYP3A5 or MDR1 polymorphisms, increases tacrolimus clearance in pediatric hematopoietic SCT. Bone marrow transplantation. 2011. Yanagisawa R, et al.
	Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenetics and genomics. 2010. Thorn Caroline F, et al.
CA VA	Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients. Pharmacogenetics and genomics. 2010. Hu Miao, et al.
	Transporter hypothesis of drug-resistant epilepsy: challenges for pharmacogenetic approaches. Pharmacogenomics. 2010. Potschka Heidrun.
CA VA	Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer. Cancer chemotherapy and pharmacology. 2010. Akasaka Keiichi, et al.
	Association of genetic polymorphisms with hepatotoxicity in patients with childhood acute lymphoblastic leukemia or lymphoma. Pediatric hematology and oncology. 2010. Horinouchi Masanori, et al.
CA VA	Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010. McLeod Howard L, et al.
VA	ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2010. Mizuno T, et al.
CA VA	Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study. Circulation. Cardiovascular genetics. 2010. Bailey Kristian M, et al.
VA	Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate. Pharmacogenetics and genomics. 2010. Stamp Lisa K, et al.
	Drug transporter pharmacogenetics in nucleoside-based therapies. Pharmacogenomics. 2010. Errasti-Murugarren Ekaitz, et al.
CA VA	ABCG2 Polymorphism Is Associated With the Low-Density Lipoprotein Cholesterol Response to Rosuvastatin. Clinical pharmacology and therapeutics. 2010. Tomlinson B, et al.
	Breast cancer resistance protein (BCRP)-mediated glyburide transport: effect of the C421A/Q141K BCRP single-nucleotide polymorphism. Drug metabolism and disposition: the biological fate of chemicals. 2010. Pollex Erika K, et al.
	Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin. American journal of obstetrics and gynecology. 2010. Hemauer Sarah J, et al.
	Pharmacogenomics of membrane transporters: past, present and future. Pharmacogenomics. 2010. Yee Sook Wah, et al.
	ABC transporters in cancer: more than just drug efflux pumps. Nature reviews. Cancer. 2010. Fletcher Jamie I, et al.
	Transporter pharmacogenetics and statin toxicity. Clinical pharmacology and therapeutics. 2010. Niemi M.
	Taxane Pathway. Pharmacogenetics and genomics. 2009. Oshiro Connie, et al.
	Pharmacogenomics in acute myeloid leukemia. Pharmacogenomics. 2009. Roumier Christophe, et al.
VA	Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression. Journal of human genetics. 2009. Cha Pei-Chieng, et al.
	Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009. van Erp Nielka P, et al.
	Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009. Hauswald Stefanie, et al.
	Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proceedings of the National Academy of Sciences of the United States of America. 2009. Woodward Owen M, et al.
	Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer chemotherapy and pharmacology. 2009. Yuan Jianhui, et al.
CA VA	ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clinical pharmacology and therapeutics. 2009. Keskitalo J E, et al.
CA VA	Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics. 2009. Keskitalo Jenni E, et al.
	Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152. The pharmacogenomics journal. 2009. Guo J, et al.
	The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Investigational new drugs. 2009. Oostendorp Roos L, et al.
	Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Advanced drug delivery reviews. 2009. Noguchi Kohji, et al.
CA VA	Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2009. Han Ji-Youn, et al.
	Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC). BMC cancer. 2009. Glaysher Sharon, et al.
	Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics. Journal of experimental therapeutics & oncology. 2009. Ishikawa Toshihisa, et al.
	Genetic variation in the proximal promoter of ABC and SLC superfamilies: liver and kidney specific expression and promoter activity predict variation. PloS one. 2009. Hesselson Stephanie E, et al.
	Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy. The International journal of biological markers. 2009. Li Xiao-Qin, et al.
CA VA	Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008. Petain Aurélie, et al.
	Synergistic interaction of ABCB1 and ABCG2 polymorphisms predicts the prevalence of toxic encephalopathy during anticancer chemotherapy. The pharmacogenomics journal. 2008. Erdilyi D J, et al.
	Breast cancer resistance protein expression and 5-fluorouracil resistance. Biomedical and environmental sciences : BES. 2008. Yuan Jian-Hui, et al.
CA VA	Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. The Journal of investigative dermatology. 2008. Warren Richard B, et al.
CA VA	Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans. Clinical pharmacology and therapeutics. 2008. Yamasaki Y, et al.
	Estimating coverage and power for genetic association studies using near-complete variation data. Nature genetics. 2008. Bhangale Tushar R, et al.
	Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica; the fate of foreign compounds in biological systems. 2008. Hagenbuch B, et al.
	Pharmacogenetics of antiretroviral agents. Current opinion in HIV and AIDS. 2008. Owen Andrew, et al.
	Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. Pharmacogenetics and genomics. 2008. Urquhart Bradley L, et al.
VA	Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008. Rudin Charles M, et al.
	Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clinical pharmacology and therapeutics. 2008. Wang L, et al.
	SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clinical pharmacology and therapeutics. 2007. Ieiri I, et al.
	Induction of hepatobiliary efflux transporters in acetaminophen-induced acute liver failure cases. Drug metabolism and disposition: the biological fate of chemicals. 2007. Barnes Sarah N, et al.
	Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007. Marsh Sharon, et al.
	Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. The pharmacogenomics journal. 2007. Marsh S, et al.
VA	Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenetics and genomics. 2007. Ho Richard H, et al.
	Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients. Drug metabolism and disposition: the biological fate of chemicals. 2007. Yamagata Tetsuo, et al.
	Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer biology & therapy. 2007. Li Jing, et al.
	Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2. Cancer science. 2007. Tamura Ai, et al.
	Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. Journal of human genetics. 2007. Imanishi Hiroyuki, et al.
CA VA	Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. Journal of the National Cancer Institute. 2006. Cusatis George, et al.
	Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clinical pharmacology and therapeutics. 2006. Oscarson Mikael, et al.
	Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006. Hahn Noah M, et al.
	Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006. Lagas Jurjen S, et al.
	Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer chemotherapy and pharmacology. 2006. Gupta Anshul, et al.
	Expression of drug pathway proteins is independent of tumour type. The Journal of pathology. 2006. Zhang W, et al.
	Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer research. 2006. Leggas Markos, et al.
CA VA	Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clinica chimica acta; international journal of clinical chemistry. 2006. Zhang Wei, et al.
	Polymorphism discovery in 51 chemotherapy pathway genes. Human molecular genetics. 2005. Freimuth Robert R, et al.
	Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005. Henningsson Anja, et al.
	ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates. Cancer research. 2005. Shafran Assaf, et al.
	MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. International journal of cancer. Journal international du cancer. 2005. Huisman Maarten T, et al.
	Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. The Journal of clinical investigation. 2005. Kager Leo, et al.
	Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer research. 2004. Stewart Clinton F, et al.
VA	Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clinical pharmacology and therapeutics. 2004. Sparreboom Alex, et al.
	High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Molecular pharmacology. 2004. Ozvegy-Laczka Csilla, et al.
	Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis. The Journal of biological chemistry. 2004. Ifergan Ilan, et al.
	Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004. Yoh Kiyotaka, et al.
	Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Molecular cancer therapeutics. 2003. Brooks Tracy A, et al.
	Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood. 2003. Ross Mary E, et al.
	Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer research. 2003. Chen Zhe-Sheng, et al.
	Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. Cancer research. 2003. Rajendra Rajeev, et al.
	Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Pharmaceutical research. 2003. Woo Jong Soo, et al.
	Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics. 2003. Zamber Charis P, et al.
	Membrane transport of folates. Vitamins and hormones. 2003. Matherly Larry H, et al.
	Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. The Journal of clinical investigation. 2002. Fellner Stephan, et al.
	Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer research. 2002. Volk Erin L, et al.
	Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells. International journal of cancer. Journal international du cancer. 2002. Stein Ulrike, et al.
	Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer research. 2000. Allen J D, et al.
	Induction of broad drug resistance in small cell lung cancer cells and its reversal by paclitaxel. International journal of cancer. Journal international du cancer. 1998. Su G M, et al.
	Kinetics and mechanisms of reduction of Cu(II) and Fe(III) complexes by soybean leghemoglobin alpha. Biochimica et biophysica acta. 1991. Bakan D A, et al.

LinkOuts

NCBI Gene:: 9429
OMIM:: 603756
UCSC Genome Browser:: NM_004827
RefSeq RNA:: NM_004827
RefSeq Protein:: NP_004818

RefSeq DNA:: NT_016354
UniProtKB:: ABCG2_HUMAN (Q9UNQ0)
Ensembl:: ENSG00000118777
GenAtlas:: ABCG2
GeneCard:: ABCG2

MutDB:: ABCG2
HuGE:: ABCG2
Comparative Toxicogenomics Database:: 9429
ModBase:: Q8IX16
HumanCyc Gene:: HS04249
HGNC:: 74

Common Searches